Drug Trial Radar · NCT02102022
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
140
Actual
Start
Nov 2014
Primary completion
Feb 2020
Study completion Feb 2020
Sponsor
- Lead sponsor
- Polaris GroupIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).
Conditions
- Advanced Gastrointestinal (GI) Malignancies
- Hepatocellular Carcinoma
- Gastric Cancer
- Colorectal Cancer
Interventions
ADI-PEG 20 plus modified FOLFOX6Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
California Pacific Medical Center
San Francisco, California
Emory University
Atlanta, Georgia
The University of Chicago Medical Center
Chicago, Illinois
The University of Kansas Cancer Center
Westwood, Kansas
Masonic Cancer Center
Minneapolis, Minnesota
Washington University
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
Oregon Health and Science University
Portland, Oregon
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Washington
Seattle, Washington
The Chinese People's Liberation Army 81 Hospital
Nanjing, Jiangsu, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
National Cancer Institute of Napoli IRCCS G. Pascale
Naples, Italy
IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Pusan National University Hospital
Busan, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Chang Gung Medical Foundation - Kaohsiung
Kaohsiung City, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
Chi Mei Hospital, Liouying
Tainan, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Chang Gung Medical Foundation - Linkou
Taoyuan, Taiwan
Royal Free Hospital
London, United Kingdom
Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.